Amgen to acquire Medigene spin-out Catherex

23 December 2015
mergers-acquisitions-big

US biotech major Amgen (Nasdaq: AMGN) has entered into an agreement to acquire 100% of USA-based Catherex, a spin-out of Germany’s Medigene (DE: MDF1).

As a main shareholder of Catherex, Medigene Inc USA is entitled to approximately 40% of payments to be made by Amgen. The company was informed about the execution of the corresponding purchase agreement by Catherex, Amgen and the shareholders of Catherex. Medigene Inc USA is a 100% subsidiary of Medigene AG.

Deal involves $10.5 million upfront payment

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology